×

Premier Selects AngioDynamics' BioFlo PICC as a Breakthrough Technology

ALBANY, N.Y., June 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that its BioFlo peripherally inserted central catheter (PICC) was one of 14 medical innovations on display in front of thousands of healthcare providers and experts at the Premier healthcare alliance's 2013 Breakthroughs Conference and Exhibition.

The BioFlo PICC was selected by clinicians and other members of Premier, a provider-owned performance improvement alliance of more than 2,800 hospitals and nearly 100,000 other care sites. It was highlighted during the conference's fifth annual Innovation Celebration, which took place on June 11, 2013, in San Antonio, Texas. The event recognizes advances in healthcare while highlighting industry suppliers committed to innovation and improving patient outcomes. Selection criteria included the uniqueness of the product, its ability to have an impact on an unmet medical need and its potential to positively impact patient care.

PICCs allow intravenous access for an extended period for chemotherapy, antibiotic delivery and other intravascular therapies. The BioFlo PICC is the only PICC manufactured with Endexo technology, a permanent and non-eluting integral polymer. Endexo is blended into the catheter shaft's polymer, creating a material that provides long-term durability. It is present throughout the catheter shaft material and is not superficial or transient like coatings or impregnated materials. The BioFlo PICC does not contain antibiotics or antimicrobials, agents potentially associated with bacterial resistance.

"BioFlo technology has shown promise in decreasing the accumulation of catheter-related thrombus without incorporation of heparin, antibiotics, antimicrobials or any other transient materials typically associated with coated or impregnated technologies, making it a potentially disruptive product in this space," said Chuck Greiner, Vice President of AngioDynamics' Vascular Access Business. "We're pleased to see established providers like Premier acknowledge the product's potential. We believe that the BioFlo PICC's inclusion in Premier's Innovation Celebration demonstrates that the product is gaining traction in the market."

"Those who attend and participate in the Innovation Celebration share Premier's commitment to providing innovative, valuable products to our members that are safe, high-quality and cost-effective," said Durral R. Gilbert, president of supply chain services, Premier. "These advancements will truly benefit providers as they work to improve the health of their communities."

Any supplier, regardless of whether the company is contracted with Premier, can be considered for participation in the Innovation Celebration. Overall, Premier contracts with more than 1,000 suppliers.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

About the Premier healthcare alliance, Malcolm Baldrige National Quality Award recipient

Premier is the nation's largest performance improvement alliance of more than 2,800 U.S. hospitals and nearly 100,000 other sites using the power of collaboration and technology to lead the transformation to coordinated, high-quality, cost-effective care. Owned by healthcare providers, Premier operates a leading purchasing network with more than $5 billion in annual savings. Premier also maintains clinical, financial and outcomes databases based on 1 in every 4 patient discharges. A world leader in measurably improving patient care, Premier has the largest performance improvement collaboratives in America, including one in partnership with the Centers for Medicare & Medicaid Services. Headquartered in Charlotte, N.C., Premier also has an office in Washington. https://www.premierinc.com. Stay connected with Premier on Facebook, Twitter, LinkedIn and YouTube.

Trademarks

AngioDynamics, the AngioDynamics logo, and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Endexo is a registered trademark of Interface Biologics Inc.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2012. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

CONTACT: Company Contact: AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Michael Polyviou/Robert Jones (212)850-6020; (646) 201-5447 mpolyviou@evcgroup.com; bjones@evcgroup.com Media Contact: EVC Group, Inc. Chris Gale (646) 201-5431 cgale@evcgroup.comSource:AngioDynamics